Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 11/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 11/20 | 0.38 |
| ▸ | ITGB7 | P26010 | 9/20 | 0.38 |
| ▸ | ITGAV | P06756 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2769223 | 0.99 | ITGB1 (0.38) | ITGB1ITGA4ITGB7ITGAVMEN1 | |
| SCHEMBL2808033 | 0.94 | ITGB1 (0.35) | ITGB1ITGA4ITGB7ITGAVALDH1A1 | |
| SCHEMBL2769475 | 0.93 | ITGB1 (0.38) | ITGB1ITGA4ITGB7ITGAVMEN1 | |
| SCHEMBL2809357 | 0.93 | ITGB1 (0.35) | ITGB1ITGA4ITGB7ITGAVMEN1 | |
| SCHEMBL2770607 | 0.93 | ITGB1 (0.38) | ITGB1ITGA4ITGB7ITGAVALDH1A1 | |
| SCHEMBL2770852 | 0.92 | ITGB1 (0.40) | ITGB1ITGA4ITGB7ITGAVKMT2A | |
| SCHEMBL2769194 | 0.90 | ITGB1 (0.50) | ITGB1ITGA4ITGB7ITGAVALDH1A1 | |
| SCHEMBL2814333 | 0.89 | ITGB1 (0.35) | ITGB1ITGA4ITGB7KMT2AALDH1A1 | |
| SCHEMBL2770210 | 0.89 | ITGB1 (0.36) | ITGB1ITGA4ITGB7ITGAVALDH1A1 | |
| SCHEMBL2771648 | 0.89 | ITGB1 (0.36) | ITGB1ITGA4ITGB7ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1763361-A2 | STEROID SPARING AGENTS AND THEIR USE | Elan Pharmaceuticals, Inc. (US) | 2007-03-21 | — | — | EP | disclosed |
| US-20060004019-A1 | Steroid sparing agents and methods of using same | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2006-01-05 | — | — | US | disclosed |
| WO-2005097162-A2 | STEROID SPARING AGENTS AND THEIR USE | ELAN PHARMACEUTICALS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004019-A1 | Steroid sparing agents and methods of using same | IL5, FCER2, CD40 | ITGB1 305/4885ITGA4 298/4885ITGB7 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.